These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

446 related items for PubMed ID: 1656030

  • 1. Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736.
    Crowley HJ, Yaremko B, Selig WM, Janero DR, Burghardt C, Welton AF, O'Donnell M.
    J Pharmacol Exp Ther; 1991 Oct; 259(1):78-85. PubMed ID: 1656030
    [Abstract] [Full Text] [Related]

  • 2. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
    Herbert JM, Bernat A, Valette G, Gigo V, Lale A, LaPlace MC, Lespy L, Savi P, Maffrand JP, Le Fur G.
    J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist.
    Tsunoda H, Sakuma Y, Harada K, Muramoto K, Katayama S, Horie T, Shimomura N, Clark R, Miyazawa S, Okano K.
    Arzneimittelforschung; 1990 Nov; 40(11):1201-5. PubMed ID: 2085331
    [Abstract] [Full Text] [Related]

  • 4. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
    Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A, García-Rafanell J, Forn J.
    J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor.
    Casals-Stenzel J, Muacevic G, Weber KH.
    J Pharmacol Exp Ther; 1987 Jun; 241(3):974-81. PubMed ID: 3598913
    [Abstract] [Full Text] [Related]

  • 6. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.
    Heuer HO, Casals-Stenzel J, Muacevic G, Weber KH.
    J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914
    [Abstract] [Full Text] [Related]

  • 7. Effects of Ro 24-4736 in antagonizing the platelet and bronchoconstrictor responses to PAF.
    O'Donnell M.
    Ann N Y Acad Sci; 1991 Dec; 629():416-8. PubMed ID: 1659287
    [No Abstract] [Full Text] [Related]

  • 8. Effect of Y-24180, a long-acting antagonist to platelet-activating factor (PAF), on PAF-induced reactions: a relationship between the partial structure of the compound and its duration of the action.
    Kagoshima M, Tomomatsu N, Iwahisa Y, Yamaguchi S, Kawakami Y, Terasawa M.
    Pharmacology; 1997 May; 54(5):261-70. PubMed ID: 9380772
    [Abstract] [Full Text] [Related]

  • 9. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
    Imanishi N, Murakami-Uchida M, Koike H, Natsume Y, Morooka S.
    Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
    [Abstract] [Full Text] [Related]

  • 10. The platelet activating factor receptor antagonist, RP 59227, blocks platelet activating factor receptors mediating liberation of reactive oxygen species in guinea pig macrophages and human polymorphonuclear leukocytes.
    Floch A, Tahraoui L, Sedivy P, Cavero I.
    J Pharmacol Exp Ther; 1991 Aug; 258(2):567-75. PubMed ID: 1650834
    [Abstract] [Full Text] [Related]

  • 11. MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor.
    Hwang SB, Lam MH, Szalkowski DM, MacIntyre DE, Bach TJ, Luell S, Meuer R, Sahoo SP, Alberts AW, Chabala JC.
    J Lipid Mediat; 1993 Jun; 7(2):115-34. PubMed ID: 8400114
    [Abstract] [Full Text] [Related]

  • 12. The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active.
    Cook NS, Bruttger O, Pally C, Hagenbach A.
    Thromb Haemost; 1993 Nov 15; 70(5):838-47. PubMed ID: 8128443
    [Abstract] [Full Text] [Related]

  • 13. Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor.
    Hwang SB, Lam MH, Alberts AW, Bugianesi RL, Chabala JC, Ponpipom MM.
    J Pharmacol Exp Ther; 1988 Aug 15; 246(2):534-41. PubMed ID: 2841449
    [Abstract] [Full Text] [Related]

  • 14. WEB 2347: pharmacology of a new very potent and long acting hetrazepinoic PAF-antagonist and its action in repeatedly sensitized guinea-pigs.
    Heuer HO.
    J Lipid Mediat; 1991 Aug 15; 4(1):39-44. PubMed ID: 1893086
    [Abstract] [Full Text] [Related]

  • 15. Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation.
    Ring PC, Seldon PM, Barnes PJ, Giembycz MA.
    Mol Pharmacol; 1993 Feb 15; 43(2):302-12. PubMed ID: 8381515
    [Abstract] [Full Text] [Related]

  • 16. Ex vivo effects of SR 27417, a novel PAF antagonist, on rabbit platelet aggregation and [3H]-PAF binding.
    Herbert JM, Laplace MC, Maffrand JP.
    J Lipid Mediat; 1992 Feb 15; 5(1):1-12. PubMed ID: 1327264
    [Abstract] [Full Text] [Related]

  • 17. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
    Herbert JM, Fraisse L, Bachy A, Valette G, Savi P, Laplace MC, Lassalle J, Roche B, Lale A, Keane PE.
    J Lipid Mediat; 1993 Aug 15; 8(1):31-51. PubMed ID: 8257776
    [Abstract] [Full Text] [Related]

  • 18. High affinity specific binding sites for tritiated platelet-activating factor in canine platelet membranes: counterparts of platelet-activating factor receptors mediating platelet aggregation.
    Tahraoui L, Floch A, Mondot S, Cavero I.
    Mol Pharmacol; 1988 Aug 15; 34(2):145-51. PubMed ID: 2842653
    [Abstract] [Full Text] [Related]

  • 19. Anti-anaphylactic activity of the novel selective histamine H1 receptor antagonist mizolastine in the rodent.
    Levrier J, Duval D, Prouteau M, Voltz C, Berry CN, Lloyd KG, Scatton B.
    Arzneimittelforschung; 1995 May 15; 45(5):559-68. PubMed ID: 7541995
    [Abstract] [Full Text] [Related]

  • 20. Influence of SK&F 95587 and BN 50730 on bronchoconstrictor responses in the cat.
    Dyson MC, Bellan JA, Minkes RK, Beckerman RC, Wegmann MJ, Braquet P, McNamara DB, Kadowitz PJ.
    J Pharmacol Exp Ther; 1990 Dec 15; 255(3):1320-7. PubMed ID: 2175802
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.